Sorbitol Dehydrogenase (SORD) Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Sorbitol Dehydrogenase (SORD) Deficiency Market Outlook

Thelansis’s “Sorbitol Dehydrogenase (SORD) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sorbitol Dehydrogenase (SORD) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sorbitol Dehydrogenase (SORD) Deficiency Overview

Sorbitol dehydrogenase deficiency (SORD Deficiency) is a progressive hereditary neuropathy that significantly impacts peripheral nerves and motor neurons, leading to considerable disability, sensory loss, and reduced mobility. Consequently, intracellular sorbitol accumulates, and this molecular alteration has been identified as the underlying cause of the disease in a specific subgroup of patients previously diagnosed with Charcot-Marie-Tooth disease (CMT2) or distal hereditary motor neuropathy (dHMN). A subtype of Charcot-Marie-Tooth disease (CMT) is caused by a mutated SORD gene, which encodes for sorbitol dehydrogenase. The mutated gene results in elevated levels of sorbitol, leading to axonal damage in the peripheral nerves. Individuals with SORD Deficiency experience a progressive form of neuropathy, typically commencing in late adolescence. This condition can substantially impede the individual’s quality of life, presenting symptoms such as limb weakness, foot deformities, tremors, sensory impairment, and difficulties with walking. Onset of SORD Deficiency symptoms typically occurs around the age of 17, although it can arise anytime between 9 and 25 years of age. Clinical diagnosis of SORD Deficiency relies on the presence of a slowly progressing neuropathy, often accompanied by foot deformities. In addition to clinical assessment of signs, symptoms, and neurophysiological evaluations, SORD Deficiency can also be confirmed through genetic testing and motor nerve conduction velocity (MNCV) testing. Currently, there are no approved pharmacological treatments for SORD Deficiency. Management of symptoms involves a multidisciplinary approach, including rehabilitative measures, physical and occupational therapy, and surgical interventions in cases of severe impairment.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Sorbitol Dehydrogenase (SORD) Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034